Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : HG-CT-1
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Made Scientific
Deal Size : Undisclosed
Deal Type : Partnership
Made Scientific and Hemogenyx Announce Technology Transfer and Manufacturing Partnership
Details : The partnership aims to advance HG-CT-1, Hemogenyx's Chimeric Antigen Receptor T-cell (CAR-T) therapy and lead clinical program for the treatment of relapsed/refractory acute myeloid leukemia.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
September 08, 2025
Lead Product(s) : HG-CT-1
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Made Scientific
Deal Size : Undisclosed
Deal Type : Partnership
Hemogenyx raises £570,000 and Director's Dealing
Details : The net proceeds will be used for Phase I clinical trial of the Company's Chimeric Antigen Receptor T-cell therapy, HG-CT-1, aimed at treating relapsed/refractory acute myeloid leukemia.
Product Name : HG-CT-1
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
August 26, 2025
Lead Product(s) : HG-CT-1,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Hemogenyx Pharmaceuticals PLC Announces Recruitment of Second Patient for Clinical Trials
Details : HG-CT-1 is a proprietary anti-FLT3 CAR-T cell therapy, being investigated for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) in adults.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 17, 2025
Lead Product(s) : HG-CT-1,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Hemogenyx Pharmaceuticals PLC Announces First-in-Human Treatment with HG-CT-1
Details : HG-CT-1, is a CAR-T cell therapy, which is being evaluated for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) in adults.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
February 24, 2025
Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/refractory AML
Details : This drug candidate is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 22, 2025
Hemogenyx Pharmaceuticals PLC Announces IRB Approval for Phase I Clinical Trial
Details : HEMO-CAR-T cell therapy is developed using Hemogenyx’s proprietary humanised monoclonal antibody. It is being evaluated for the treatment of r/r acute myeloid leukemia.
Product Name : HEMO-CAR-T
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
November 22, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Prevail Partners
Deal Size : $0.3 million
Deal Type : Financing
Hemogenyx Pharmaceuticals PLC Announces Strategic Investment from Prevail Partners, LLC
Details : THe proceeds will be used in clinical services and technologies for the Company's upcoming Phase I of an anti-FLT3 CAR-T cells in pediatric subjects with R/R AML and a subset of ALL.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 02, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Prevail Partners
Deal Size : $0.3 million
Deal Type : Financing
Lead Product(s) : HEMO-CAR-T
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Hemogenyx Pharmaceuticals PLC Announces CDX Development Update
Details : HEMO-CAR-T cell therapy is developed using Hemogenyx’s proprietary humanized monoclonal antibody. It is being evaluated in preclinical studies for the treatment of r/r acute myeloid leukemia.
Product Name : HEMO-CAR-T
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
September 02, 2024
Lead Product(s) : HEMO-CAR-T
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HEMO-CAR-T
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Hemogenyx Pharmaceuticals PLC Announces Submission of Complete Response to Clinical Hold
Details : HEMO-CAR-T cell therapy is developed using Hemogenyx’s proprietary humanised monoclonal antibody. It is being evaluated in preclinical studies for the treatment of acute myeloid leukemia.
Product Name : HEMO-CAR-T
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
January 16, 2024
Lead Product(s) : HEMO-CAR-T
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Hemogenyx Pharmaceuticals PLC Announces CBR Expanded to Treatment of Cancer
Details : Human macrophages, a type of immune cells, programmed with a purpose designed CBR, were able to eliminate Non-Hodgkin Lymphoma derived cells with high efficiency in vitro.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 27, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable